Bausch + Lomb Advances Development of Oral Treatment for Dry AMD
Bausch + Lomb has made progress in developing tonabersat (BL1243), an oral treatment for dry age-related macular degeneration, following a meeting with the U.S. Food and Drug Administration (FDA). The company reported that discussions provided greater clarity on regulatory expectations, which could help streamline future development steps. Dry AMD is a leading cause of vision loss among older adults, affecting millions globally. Bausch + Lomb's oral treatment represents an innovative approach to managing this condition compared to current therapies like injections or eye drops. The FDA feedback appears constructive and may support the company’s clinical trial planning for tonabersat. The development progress could enhance investor confidence in Bausch + Lomb, particularly as it explores new therapeutic options within ophthalmology.
Tickers: $BLCO
Topics: clinical trials drug development macular degeneration treatment